Effects of Silymarin (Milk thistle fruit extract) on liver fibrosis in Nonalcoholic Fatty Liver Disease
Phase 2
Recruiting
- Conditions
- on alcoholic fatty liver disease
- Registration Number
- SLCTR/2017/016
- Lead Sponsor
- Department of Hepatology Bangabandhu Sheikh Mujib Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Fatty liver in ultrasonography of hepatobilliary system
Exclusion Criteria
1.Co-infection with Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV)
2.History of significant alcoholism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie silymarin's antifibrotic effects in nonalcoholic fatty liver disease?
How does silymarin compare to vitamin E or pioglitazone in reducing liver fibrosis in NAFLD patients?
Which biomarkers correlate with silymarin response in nonalcoholic steatohepatitis (NASH) progression?
What adverse events are associated with long-term silymarin use in chronic liver disease management?
Are there synergistic effects when combining silymarin with GLP-1 receptor agonists for NAFLD treatment?